Rhodium-Rhenium Alloy Nanozymes for Non-inflammatory Photothermal Therapy

ACS Appl Mater Interfaces. 2024 May 1;16(17):21653-21664. doi: 10.1021/acsami.4c02550. Epub 2024 Apr 22.

Abstract

Analogous to thermal ablation techniques in clinical settings, cell necrosis induced during tumor photothermal therapy (PTT) can provoke an inflammatory response that is detrimental to the treatment of tumors. In this study, we employed a straightforward one-step liquid-phase reduction process to synthesize uniform RhRe nanozymes with an average hydrodynamic size of 41.7 nm for non-inflammatory photothermal therapy. The obtained RhRe nanozymes showed efficient near-infrared (NIR) light absorption for effective PTT, coupled with a remarkable capability to scavenge reactive oxygen species (ROS) for anti-inflammatory treatment. After laser irradiation, the 4T1 tumors were effectively ablated without obvious tumor recurrence within 14 days, along with no obvious increase in pro-inflammatory cytokine levels. Notably, these RhRe nanozymes demonstrated high biocompatibility with normal cells and tissues, both in vitro and in vivo, as evidenced by the lack of significant toxicity in female BALB/c mice treated with 10 mg/kg of RhRe nanozymes over a 14 day period. This research highlights RhRe alloy nanoparticles as bioactive nanozymes for non-inflammatory PTT in tumor therapy.

Keywords: anti-inflammatory; nanozyme; photothermal therapy; reactive oxygen species; tumor ablation.

MeSH terms

  • Alloys* / chemistry
  • Alloys* / pharmacology
  • Animals
  • Cell Line, Tumor
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C*
  • Photothermal Therapy*
  • Reactive Oxygen Species / metabolism
  • Rhenium* / chemistry
  • Rhenium* / pharmacology
  • Rhodium* / chemistry
  • Rhodium* / pharmacology

Substances

  • Rhodium
  • Alloys
  • Rhenium
  • Reactive Oxygen Species